Development of combined vaccines: manufacturers' viewpoint.
Rapid and exciting research breakthroughs in the fields of immunology and molecular biology in recent years have greatly enhanced the potential for developing new vaccines or improving existing ones. The resulting rising number of diseases that can be prevented by vaccination, coupled with the growing trend of preferring cost-effective preventive medical interventions over expensive therapeutic modalities, has increased the complexity of administering to all those who need them, the many different vaccines that will soon be available. Hence attention in the field of vaccinology is now focusing on the development of combined vaccines that, in a few inoculations, can elicit protection against as many diseases as possible. Some of the recent achievements, future objectives and difficulties of vaccine manufacturers in the development of combined vaccines are surveyed.
André
F E
FE
SmithKline Beecham Biologicals, Rixensart, Belgium.
D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000276:immunology; D004345:Drug Industry / Q000191:economics; D017325:Hepatitis B Vaccines / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined / Q000191:economics / Q000592:standards; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic / Q000276:immunology
D015721:Diphtheria-Tetanus-Pertussis Vaccine; C075654:Engerix-B; D017325:Hepatitis B Vaccines; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic